Labcorp to acquire Personal Genome Diagnostics in $575m worth deal
Labcorp, a North Carolina-based life sciences company, has agreed to acquire Personal Genome Diagnostics (PGDx), a provider of liquid biopsy and tissue-based genomic products and ... Read More
Sun Pharma Advanced Research signs licensing deal with Biomodifying
Sun Pharma Advanced Research Company (SPARC) has signed an agreement with US-based Biomodifying for the exclusive licensing of the latter’s intellectual property (IP), including all ... Read More
Zydus Cadila gets FDA final approval for Decitabine injection
Zydus Cadila has secured final approval from the US Food and Drug Administration (FDA) for the commercialization of the cancer medication Decitabine for Injection in ... Read More
Natco Pharma launches PrNAT-LENALIDOMIDE Capsules in Canada
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer drug Revlimid. The launch was announced earlier ... Read More
DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric ... Read More
HCG buys oncology hospital labs and clinical trials business of Strand Lifesciences
HealthCare Global Enterprises Limited (HCG) said that it has acquired oncology hospital labs and clinical trials business of Strand Lifesciences for around INR 81 crores ... Read More
Dr. Reddy’s Labs signs deal worth up to $150m to sell E7777 rights to Citius
Dr. Reddy's Laboratories (Dr. Reddy's Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets to ... Read More
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More
Infosys opens Rs 25.5cr OPD block at Kidwai Memorial Institute of Oncology
Infosys said that its philanthropic and CSR arm — Infosys Foundation has wrapped up construction of a multi-disciplinary outpatient department (OPD) block at the Kidwai ... Read More
Lantern Pharma bags FDA orphan drug status for LP-184 in pancreatic cancer
Lantern Pharma has secured orphan drug designation for its small molecule drug candidate LP-184 from the US Food and Drug Administration (FDA) for the treatment ... Read More